xtraurogenital screening for agents of sexually transmitted infection (STI) has been advocated in a number of clinical and public health scenarios (1) . Studies have reported increased rates of Chlamydia trachomatis and Neisseria gonorrhoeae detection from pharyngeal and rectal specimens via nucleic acid amplification testing compared to rates found with culture (2-7). Moreover, differences in clinical and in vitro detection rates yielded by transcription-mediated amplification (TMA) versus DNA amplification modalities have been demonstrated (4) (5) (6) (7) (8) (9) , likely owing to target capture-based removal of endogenous inhibitors (10, 11) . Detection of Trichomonas vaginalis RNA from pharyngeal specimens (12) and Mycoplasma genitalium RNA from urine specimens (13) of male STI clinic attendees has recently been reported on the basis of commercial TMA assays. The purpose of this investigation was to assess both the capacity of TMA for detection of M. genitalium from pharyngeal and rectal specimens and the potential for multispecimen analysis in the overall identification of male carriers of STI agents.
(Results of this work were presented in part at ASM Microbe, Boston, MA, 16 to 20 June 2016.)
With an Institutional Review Board-approved protocol, screening practices for male attendees of a Milwaukee, WI, STI clinic were audited from March 2014 through December 2015. The high-STI-prevalence nature of this community was noted previously (14) . Aliquots of first-void urine were dispensed into Aptima urine specimen transport tubes (Hologic, San Diego, CA). Pharyngeal and rectal swab specimens were obtained using the Aptima unisex swab specimen collection kit (Hologic).
C. trachomatis-and N. gonorrhoeae-specific analyses from all collections were performed with the Aptima Combo 2 assay (Hologic), including laboratory-validated assessments of pharyngeal and rectal specimens. T. vaginalis detection occurred via an Aptima Trichomonas vaginalis assay (Hologic) that was laboratory validated for analysis of male urine and pharyngeal specimens. Detection of M. genitalium occurred via TMA-based analyte-specific reagent (ASR) (Hologic). All assays were performed on Tigris DTS (Hologic). M. genitalium ASR relative light unit output of Ն50,000 signified a positive result. The significance test of proportions was used to determine whether changes in detection rates were significant.
Collection of one and two specimens was used to manage 4.4% and 41.3% of patient encounters, respectively (Fig. 1 ). The two most commonly detected STI agents from pharyngeal collections were N. gonorrhoeae (3.3%) and T. vaginalis (1.5%) (Fig. 2) . M. genitalium was detected from 0.9% of pharyngeal specimens. Detection rates of M. genitalium (5.8%), C. trachomatis (6.0%), and N. gonorrhoeae (6.4%) from rectal specimens were generally similar to those of M. genitalium (6.6%) and C. trachomatis (5.1%) from urine specimens (Fig. 2) . Analysis of rectal specimens for T. vaginalis was not attempted because previous data demonstrated 0% prevalence in this population from this specimen source (12) .
Traditional molecular STI assays have targeted C. trachomatis and N. gonorrhoeae. TMA-based detection of other STI agents has been documented from male urogenital (T. vaginalis, M. genitalium) and pharyngeal (T. vaginalis) specimens (12, 13, 15, 16) . C. trachomatis and N. gonorrhoeae screening from both urine and extraurogenital sources in this study resulted in 228 instances of STI (15.3% incidence rate) (Fig. 3) . Addition of T. vaginalis and M. genitalium analytes into the comprehensive screen increased incidence rates to 17.4% (P ϭ 0.11 versus C. trachomatis and N. gonorrhoeae screening) and 23.9% (P Ͻ 0.0002 versus combined C. trachomatis, N. gonorrhoeae, and T. vaginalis screening), respectively.
A total of 1,493 clinic encounters resulted in the collection of 1,465 urine specimens, 1,443 pharyngeal specimens, and 823 rectal specimens. This numeric rank formulated the basis of the sequential order of the analysis presented in Fig. 4 . Screening only urine for all four analytes resulted in 205 (13.7%) instances of STI diagnosis (Fig. 4) . This value increased (Fig. 4) ; addition of pharyngeal and rectal gonorrhoeae should be performed in MSM who have received oral intercourse during that interval. Although pharyngeal C. trachomatis screening is not a recommendation, studies have described a propensity of pharyngeal C. trachomatis carriage to result in disease transmission to genital sites (17, 18) . More-frequent screening may be indicated per additional sexual risk factors.
Perhaps as a result of these updated guidelines, the percentage of encounters resulting in multiple specimen collections in this study (95.6%) exceeded that from one previous survey of this STI clinic population (64.2%) (12) . Not only did multisource sampling and multianalyte testing in an STI clinic population provide general benefit, a rather high-risk, susceptible population may also be appreciated when analyzing the demographics characterized by extraurogenital M. genitalium carriage. The median ages of attendees with detectable pharyngeal and rectal M. genitalium were 24.0 and 24.5 years, respectively. Men with detectable pharyngeal and rectal M. genitalium averaged 10.4 and 7.2 sexual partners, respectively, over the previous 12 months. Moreover, 93.3% and 81.8% of men with detectable rectal and pharyngeal M. genitalium, respectively, engaged in homosexual practices.
M. genitalium detection in pharyngeal and rectal specimens was confirmed by positive results generated by repeat M. genitalium ASR from 92.3% and 91.5% of specimens, respectively. Previous data revealed that repeat TMA analysis performed the same as alternative target testing for confirmation of STI agent detection (19, 20) . In general, specificity of M. genitalium ASR within a female acute and subacute population was demonstrated by 98.8% concordance between results from M. genitalium ASR and alternative target testing (21) . In conclusion, procurement of rectal, pharyngeal, and urine specimens increases overall identification of male STI carrier status. Moreover, the advent of commercial M. genitalium ASR may result in a substantial percentage of sole M. genitalium detection within this demographic. Additional studies are warranted to determine financial and disease transmission impacts relative to routine incorporation of this assay into a comprehensive STI screening algorithm.
